| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/21/2009 | CN101347518A Effective component of red paeonia and preparation and use thereof |
| 01/21/2009 | CN101347516A Method for preparing total free anthraquinones extract from rhubarb |
| 01/21/2009 | CN101347513A Medicine for treating cancer |
| 01/21/2009 | CN101347510A Use of Stephania delavayi extract in preparing anti-tumor medicament |
| 01/21/2009 | CN101347509A Effective component of Sinomenium acutum and preparation and use thereof |
| 01/21/2009 | CN101347508A Effective component of Sinomenium acutum and preparation and use thereof |
| 01/21/2009 | CN101347506A Anti-cancer medicine composition |
| 01/21/2009 | CN101347504A Effective component of salvia root and preparation thereof and use |
| 01/21/2009 | CN101347502A Effective component of selfheal and preparation and use thereof |
| 01/21/2009 | CN101347501A Effective component of Rabdosia amethystoides and preparation and use thereof |
| 01/21/2009 | CN101347500A Effective component of rabdosia and preparation and use thereof |
| 01/21/2009 | CN101347497A Effective component of vietnamese sophora root and preparation and use thereof |
| 01/21/2009 | CN101347496A Effective component of Spatholobus stem and preparation and use thereof |
| 01/21/2009 | CN101347493A Use of shamrock extract in preparing anti-tumor medicament |
| 01/21/2009 | CN101347484A Effective component of Atractylodes macrocephala and preparation and use thereof |
| 01/21/2009 | CN101347480A Effective component of inula flower and preparation and use thereof |
| 01/21/2009 | CN101347479A Effective component of acanthopanax and preparation and use thereof |
| 01/21/2009 | CN101347478A Acanthopanax root effective component and preparation and use thereof |
| 01/21/2009 | CN101347475A Use of Alstonia mairei extract in preparing anti-tumor medicament |
| 01/21/2009 | CN101347474A Effective component of Chinese angelica and preparation and use thereof |
| 01/21/2009 | CN101347473A Effective component of creat and preparation and use thereof |
| 01/21/2009 | CN101347468A Effective component of common camptotheca fruit and preparation as well as use thereof |
| 01/21/2009 | CN101347467A Effective component of common camptotheca fruit and preparation as well as use thereof |
| 01/21/2009 | CN101347459A Medicine for treating cancer |
| 01/21/2009 | CN101347456A Medicinal use of mole |
| 01/21/2009 | CN101347455A Carbon-encapsulated iron nanoparticles and use thereof as vector of medicament for treating liver cancer |
| 01/21/2009 | CN101347446A Medicament composition containing astragalus polysaccharide and ginseng bud saponin and uses thereof |
| 01/21/2009 | CN101347445A Medicament composition containing astragalus polysaccharide and ginseng bud polysaccharide, and uses thereof |
| 01/21/2009 | CN101347442A Use of Kelituoxin in preparing anti-tumor medicament with multidrug resistance |
| 01/21/2009 | CN101347433A Pharmacy use of 4-aniline quinazoline derivatives |
| 01/21/2009 | CN101347425A Uses of ampelopsin and total flavone valid target rich in ampelopsin in preparing medicament for preventing and treating prostate gland cancer |
| 01/21/2009 | CN101347412A Amifostine trihydrate crystal lyophilized preparation and method of preparing the same |
| 01/21/2009 | CN101347410A Anticancer sustained-release injection containing octadecyl dimethyl-4-piperidine phosphate |
| 01/21/2009 | CN101347409A Sustained-release injection containing octadecyl dimethyl-4-piperidine phosphate |
| 01/21/2009 | CN101347403A Method for preparing organic metal compound anti-cancer medicine with electrostatic spinning technique |
| 01/21/2009 | CN100453645C Antibodies against insulin-like growth factor i receptor and uses thereof |
| 01/21/2009 | CN100453556C Multispecific deimmunized CD3-binders |
| 01/21/2009 | CN100453549C 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/21/2009 | CN100453118C Antientity tumour medicinal composition containing topoenzyme inhibitor |
| 01/21/2009 | CN100453113C Externally applied transdermal Chinese medicinal formulation for treating skin cancer |
| 01/21/2009 | CN100453091C Capsule of purple sweet potato, its production and application |
| 01/21/2009 | CN100453088C Marsdenia tenacissima soft capsule and its preparation method |
| 01/21/2009 | CN100453077C Injectable micelle prepn containing garcinolic acid and its prepn process |
| 01/21/2009 | CN100453076C Application of phenhexyl isothiocyanate in preparation of medicament for treating leukemia |
| 01/21/2009 | CN100453071C Oral resveratrol multi-phase liposome and preparation method thereof |
| 01/20/2009 | US7479564 e.g. 6-ethyl-5-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-5H-[1,3]dioxolo[4,5-f]benzimidazole; prostaglandin E2 receptor antagonists; arthritis, hyperalgesia, uterine contraction, digestive peristalsis, awakeness, blood pressure, platelet function, bone metabolism, angiogenesis |
| 01/20/2009 | US7479543 chimeric antibodies comprising variable domain peptides, DNA codes for the antibodies, expression vectors, host cells and a process of culturing the host cells to produce the monoclonal antibodies, used for immunotherapy; nonimmunogenic |
| 01/20/2009 | US7479541 and fusion proteins with green fluorescent protein, used for modulating cell differentiation and apoptosis, including cell formation of tissues |
| 01/20/2009 | US7479539 Hedgehog fusion proteins |
| 01/20/2009 | US7479504 Edg receptor agonists |
| 01/20/2009 | US7479501 Heteroaryl-cyclic acetals |
| 01/20/2009 | US7479499 Methods of using thalidomide in combination with irinotecan |
| 01/20/2009 | US7479495 N-heterocyclic inhibitors of TNF-α expression |
| 01/20/2009 | US7479376 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 01/20/2009 | US7479290 for preparing Solanum alkaloid glycosides; Solanum is subjected to methanol extraction, drying the extract and dissolving in a weak volatile acid and centrifuged, the supernatant is precipitated using a volatile base; high purity |
| 01/20/2009 | US7479287 Methods of inhibiting proliferation of cells |
| 01/20/2009 | US7479266 Polyvalent conjugate vaccine for cancer |
| 01/20/2009 | CA2517245C Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| 01/20/2009 | CA2502856C Intermediates for retroviral protease inhibiting compounds |
| 01/20/2009 | CA2477839C Nitrogen containing heterocyclic compounds and medicines containing the same |
| 01/20/2009 | CA2468916C A stable oxaliplatin solution formulation |
| 01/20/2009 | CA2423252C Photosensitisers |
| 01/20/2009 | CA2423020C Use of antiprogestins for the induction of apoptosis in a cell |
| 01/20/2009 | CA2383241C Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles |
| 01/20/2009 | CA2373484C Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs |
| 01/20/2009 | CA2372836C Substituted pyrrolidines as cell adhesion inhibitors |
| 01/20/2009 | CA2339961C Isoquinoline derivatives with angiogenesis inhibiting activity |
| 01/20/2009 | CA2322204C 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| 01/20/2009 | CA2305621C Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/20/2009 | CA2293368C Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
| 01/20/2009 | CA2264570C Invasion-inducing agents and invasion-inhibitors for use in wound healing and cancer |
| 01/20/2009 | CA2137822C Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes |
| 01/15/2009 | WO2009009739A2 Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer |
| 01/15/2009 | WO2009009727A2 Ghrh analogs and therapeutic uses thereof |
| 01/15/2009 | WO2009009173A2 Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases |
| 01/15/2009 | WO2009009132A1 Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer |
| 01/15/2009 | WO2009009063A1 Immunotherapy for hematological malignancies |
| 01/15/2009 | WO2009009059A1 Spiro compounds as antagonists of tgf-beta |
| 01/15/2009 | WO2009009016A1 Combination anti-cancer therapy |
| 01/15/2009 | WO2009008992A2 Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 |
| 01/15/2009 | WO2009008748A1 Pyrazolo[1,5-a]pyridines and their use in cancer therapy |
| 01/15/2009 | WO2009008508A1 Antitumor agent comprising sulfostin and sulfostin-related compound as the active ingredient |
| 01/15/2009 | WO2009008461A1 Pharmaceutical composition for disease caused by proliferation of sex hormone sensitive cell |
| 01/15/2009 | WO2009008371A1 Di(arylamino)aryl compound |
| 01/15/2009 | WO2009008345A1 Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound |
| 01/15/2009 | WO2009008176A1 Therapeutic agent for lymphoma |
| 01/15/2009 | WO2009007753A2 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer |
| 01/15/2009 | WO2009007751A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 01/15/2009 | WO2009007750A1 Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| 01/15/2009 | WO2009007749A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 01/15/2009 | WO2009007748A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 01/15/2009 | WO2009007700A1 Treatment of melanoma |
| 01/15/2009 | WO2009007677A2 Dsb repair- inhibitors as anti-tumour agents |
| 01/15/2009 | WO2009007457A2 Compounds and methods for modulating rho gtpases |
| 01/15/2009 | WO2009007427A2 Novel antibodies inhibiting c-met dimerization, and uses thereof |
| 01/15/2009 | WO2009007422A1 Thienopyrimidylamines as modulators of the ep2 receptor |
| 01/15/2009 | WO2009007399A1 New compounds as hsp90 inhibitors |
| 01/15/2009 | WO2009007390A2 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors |
| 01/15/2009 | WO2009007388A1 Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt |
| 01/15/2009 | WO2009007348A2 Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs |